Phase 2
Intervention Type
Intravenous (IV) Injection
Funder Type

Drug Details

CM4620-IE is a potent and selective small molecule CRAC channel inhibitor that prevents CRAC channel overactivation, which can cause pulmonary endothelial damage and cytokine storm in COVID-19.

Study Purpose

This open-label randomized controlled study will evaluate safety, efficacy, and the pharmacokinetic profile of CM4620-IE in patients with severe COVID-19 pneumonia. Forty patients on low flow oxygen and forty patients on high flow oxygen will receive 2.0 mg/kg of CM4620-IE by continuous IV infusion on Day 1, followed by 1.6 mg/kg for days 2 and 3. Another 20 patients of each will receive local standard of care only. The infusion of CM4620-IE will start within 8 hours from the time the patient or LAR provides informed consent.

Find a Clinical Trial


footer_txt_bblBook a PFF Ambassador for your event.   Call 844.TalkPFF >